Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST

American Journal of Surgical Pathology

Volumn 40, Issue 4, 2016, Pages 479-489

  Prieto Granada, Carlos N ^a   Wiesner, Thomas ^a   Messina, Jane L ^a   Jungbluth, Achim A ^a   Chi, Ping ^a,b,c   Antonescu, Cristina R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

EED; H3K27me3; Malignant peripheral nerve sheath tumor; Neuro fibromatosis 1; Polycomb repressor complex 2; SUZ12

Indexed keywords

HISTONE; HISTONE DEMETHYLASE; KDM6B PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CHILD; DNA METHYLATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NEURILEMMOMA; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FEMALE; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MALE; MIDDLE AGED; NEURILEMMOMA; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84949463785     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000564     Document Type: Article

References (52)

1. Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26, 758 cases. Int J Cancer. 2006;119:2922-2930.
2. Ducatman BS, Scheithauer BW. Postirradiation neurofibrosarcoma. Cancer. 1983;51:1028-1033.
3. Foley KM, Woodruff JM, Ellis FT, et al. Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol. 1980;7:311-318.
4. Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295-319.
5. Scheithauer BW, Woodruff JM, Erlandson RA, et al. Tumors of the Peripheral Nervous System. Washington, DC: Armed Forces Institute of Pathology; 1999.
6. Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol. 2010;34:1504-1513.
7. Thway K, Fisher C. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 2014;18:109-116.
8. Kang Y, Pekmezci M, Folpe AL, et al. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014;27:55-61.
9. Karamchandani JR, Nielsen TO, van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohisto-chem Mol Morphol. 2012;20:445-450.
10. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291-1298.
11. Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227-1232.
12. De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247-251.
13. Zhang M, Wang Y, Jones S, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1170-1172.
14. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298:1039-1043.
15. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21-29.
16. Matsunou H, Shimoda T, Kakimoto S, et al. Histopathologic and immunohistochemical study of malignant tumors of peripheral nerve sheath (malignant schwannoma). Cancer. 1985;56:2269-2279.
17. Nakajima T, Watanabe S, Sato Y, et al. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol. 1982;6:715-727.
18. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest. 1983;49: 299-308.
19. Wick MR, Swanson PE, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases. Am J Clin Pathol. 1987;87:425-433.
20. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol. 2000;190:31-38.
21. Luscan A, Vidaud D, Ortonne N, et al. PRC2 alterations in NF1-associated malignant peripheral nerve sheath tumors: schwann cells with no complex. Med Sci (Paris). 2014;30:733-735.
22. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469:343-349.
23. Yuan W, Wu T, Fu H, et al. Dense chromatin activates polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science. 2012;337:971-975.
24. Kehrer-Sawatzki H, Kluwe L, Sandig C, et al. High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. Am J Hum Genet. 2004;75:410-423.
25. Petek E, Jenne DE, Smolle J, et al. Mitotic recombination mediated by the JJAZF1 (KIAA0160) gene causing somatic mosaicism and a new type of constitutional NF1 microdeletion in two children of a mosaic female with only few manifestations. J Med Genet. 2003;40: 520-525.
26. Pelmus M, Guillou L, Hostein I, et al. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol. 2002;26:1434-1440.
27. Scheithauer BW, Amrami KK, Folpe AL, et al. Synovial sarcoma of nerve. Hum Pathol. 2011;42:568-577.
28. Jagdis A, Rubin BP, Tubbs RR, et al. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009;33:1743-1751.
29. Knosel T, Heretsch S, Altendorf-Hofmann A, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer. 2010;46: 1170-1176.
30. Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 2007;31: 240-246.
31. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009;22:872-878.
32. Smith TA, Machen SK, Fisher C, et al. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol. 1999; 112:641-648.
33. Mitchell A, Scheithauer BW, Doyon J, et al. Malignant perineur-ioma (malignant peripheral nerve sheath tumor with perineural differentiation). Clin Neuropathol. 2012;31:424-429.
34. Rosenberg AS, Langee CL, Stevens GL, et al. Malignant peripheral nerve sheath tumor with perineurial differentiation: "malignant perineurioma". J Cutan Pathol. 2002;29:362-367.
35. Coindre JM, Hostein I, Benhattar J, et al. Malignant peripheral nerve sheath tumors are t(X;18)-negative sarcomas. Molecular analysis of 25 cases occurring in neurofibromatosis type 1 patients, using two different RT-PCR-based methods of detection. Mod Pathol. 2002;15:589-592.
36. Guillou L, Coindre J, Gallagher G, et al. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol. 2001;32:105-112.
37. O'Sullivan MJ, Kyriakos M, Zhu X, et al. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod Pathol. 2000;13:1253-1263.
38. Reuss DE, Habel A, Hagenlocher C, et al. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. Acta Neuropathol. 2014;127:565-572.
39. Mohamed A, Gonzalez RS, Lawson D, et al. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immu-nohistochem Mol Morphol. 2013;21:506-510.
40. Palla B, Su A, Binder S, et al. SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics. Am J Derma-topathol. 2013;35:576-581.
41. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35:1014-1019.
42. Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol. 2012;25:505-515.
43. Kacerovska D, Michal M, Kutzner H, et al. Metastatic desmoplastic malignant melanoma associated with low-grade myofibroblastic sarcoma. Am J Dermatopathol. 2009;31:490-494.
44. Kiuru M, McDermott G, Berger M, et al. Desmoplastic melanoma with sarcomatoid dedifferentiation. Am J Surg Pathol. 2014;38: 864-870.
45. Zingg D, Debbache J, Schaefer SM, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015;6:6051, 1-17.
46. Kampilafkos P, Melachrinou M, Kefalopoulou Z, et al. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor. Am J Dermatopathol. 2015;37:138-144.
47. Pytel P, Taxy JB, Krausz T. Divergent differentiation in malignant soft tissue neoplasms: the paradigm of liposarcoma and malignant peripheral nerve sheath tumor. Int J Surg Pathol. 2005;13:19-28.
48. Binh MB, Guillou L, Hostein I, et al. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk: a study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol. 2007;31:1557-1566.
49. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31:1476-1489.
50. Andersson J, Sihto H, Meis-Kindblom JM, et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29:1170-1176.
51. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibroma-tosis type 1 patients. J Pathol. 2004;202:80-85.
52. Liegl B, Hornick JL, Antonescu CR, et al. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol. 2009;33:218-226.